Abstract:The unlimited expansion of human progenitor cells in vitro could unlock many prospects for regenerative medicine. However, it remains an important challenge as it requires the decoupling of the mechanisms supporting progenitor self-renewal and expansion from those mechanisms promoting their differentiation. This study focuses on the expansion of human pluripotent stem (hPS) cell-derived pancreatic progenitors (PP) to advance novel therapies for diabetes. We obtained mechanistic insights into PP expansion requirements and identified conditions for the robust and unlimited expansion of hPS cell-derived PP cells under GMP-compliant conditions through a hypothesis-driven iterative approach. We show that the combined stimulation of specific mitogenic pathways, suppression of retinoic acid signaling, and inhibition of selected branches of the TGFβ and Wnt signaling pathways are necessary for the effective decoupling of PP proliferation from differentiation. This enabled the reproducible, 2000-fold, over 10 passages and 40–45 d, expansion of PDX1 + /SOX9 + /NKX6-1 + PP cells. Transcriptome analyses confirmed the stabilization of PP identity and the effective suppression of differentiation. Using these conditions, PDX1 + /SOX9 + /NKX6-1 + PP cells, derived from different, both XY and XX, hPS cell lines, were enriched to nearly 90% homogeneity and expanded with very similar kinetics and efficiency. Furthermore, non-expanded and expanded PP cells, from different hPS cell lines, were differentiated in microwells into homogeneous islet-like clusters (SC-islets) with very similar efficiency. These clusters contained abundant β-cells of comparable functionality as assessed by glucose-stimulated insulin secretion assays. These findings established the signaling requirements to decouple PP proliferation from differentiation and allowed the consistent expansion of hPS cell-derived PP cells. They will enable the establishment of large banks of GMP-produced PP cells derived from diverse hPS cell lines. This approach will streamline SC-islet production for further development of the differentiation process, diabetes research, personalized medicine, and cell therapies.

Human Expandable Pancreatic Progenitor–derived Β Cells Ameliorate Diabetes

In Vitro Expansion of Pancreatic Islet Clusters Facilitated by Hormones and Chemicals.

Small Molecules Facilitate the Reprogramming of Mouse Fibroblasts into Pancreatic Lineages

Chemical Strategies for Pancreatic Β Cell Differentiation, Reprogramming, and Regeneration

Recent advances and potential applications of human pluripotent stem cell-derived pancreatic cells

Regulation of multiple signaling pathways promotes the consistent expansion of human pancreatic progenitors in defined conditions

Chemical Combinations Potentiate Human Pluripotent Stem Cell-Derived 3D Pancreatic Progenitor Clusters Toward Functional Β Cells

Conversion of Immortal Liver Progenitor Cells into Pancreatic Endocrine Progenitor Cells by Persistent Expression of Pdx‐1

Human pancreatic beta-like cells converted from fibroblasts

Targeted Derivation of Organotypic Glucose- and GLP-1-Responsive Β Cells Prior to Transplantation into Diabetic Recipients.

The reprogrammed pancreatic progenitor-like intermediate state of hepatic cells is more susceptible to pancreatic beta cell differentiation.

Highly Efficient Differentiation of Human ES Cells and Ips Cells into Mature Pancreatic Insulin-Producing Cells

Dual Inhibition of BMP and WNT Signals Promotes Pancreatic Differentiation from Human Pluripotent Stem Cells

LINC MIR503HG Controls SC‐β Cell Differentiation and Insulin Production by Targeting CDH1 and HES1

Lineage Reprogramming: A Promising Road for Pancreatic β Cell Regeneration.

Pancreatic Beta Cell Regeneration Induced By Clinical And Preclinical Agents

P21cip-overexpression in the Mouse Beta Cells Leads to the Improved Recovery from Streptozotocin-Induced Diabetes.

Establishment of human pluripotent stem cell-derived pancreatic β-like cells in the mouse pancreas

Evaluation of Islets Derived from Human Fetal Pancreatic Progenitor Cells in Diabetes Treatment

Generation of Insulin-Producing Cells from PDX-1 Gene-Modified Human Mesenchymal Stem Cells.

Forward programming of hiPSCs towards beta-like cells using Ngn3, Pdx1, and MafA